Good Manufacturing Practice for Drugs (China)
China's GMP for drugs (2010 Revision), administered by the NMPA under the Drug Administration Law. Structured similarly to EU GMP with a main text and appendices (e.g. sterile products), it raised Chinese GMP substantially toward international norms.
What this does not cover
stated in the document's own scope- Covers GMP for drug manufacture; distribution is governed by the separate Good Supply Practice framework.
- Sets manufacturing GMP, not the drug-registration/approval decision, which follows the registration provisions of the Drug Administration Law.
- Provides the general GMP plus product-specific appendices, not the analytical monographs, which come from the Pharmacopoeia of the People’s Republic of China.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
China’s Good Manufacturing Practice for drugs, in its 2010 Revision, is the national GMP the NMPA administers. It is structured much like EU GMP, with a main text setting the general requirements and a series of appendices covering specific areas such as sterile products, biological products and traditional Chinese medicine. The 2010 Revision raised Chinese GMP substantially toward international norms, tightening expectations for the quality system, premises and equipment, documentation, production, and quality control. Manufacturers must implement it to hold the production authorisation required to make drugs in China.
Scope & applicability
Drug manufacturers supplying the Chinese market. Appendices cover sterile drugs, APIs, biological products, and traditional Chinese medicine.
Legal basis & how it acquires force
The GMP is administered under China’s Drug Administration Law, the statute that governs drug manufacture, distribution and registration, and its implementing regulations. The GMP itself was issued as a ministerial measure with the force of regulation, so it is binding rather than advisory. Oversight rests with the National Medical Products Administration (NMPA) and its provincial counterparts, and GMP compliance is tied to the drug-manufacturing licence a site must obtain and maintain to produce medicines for the Chinese market.
Document structure
| Part | Covers |
|---|---|
| Main text — quality management | The pharmaceutical quality system and quality-unit responsibilities |
| Personnel, premises, and equipment | Organisation and training, and facility and equipment requirements |
| Documentation and production | The documentation system and the control of manufacturing operations |
| Quality control and assurance | The quality-control laboratory, quality assurance, and product release |
| Appendix — sterile products | Additional requirements for the manufacture of sterile medicines |
| Further appendices | Specific requirements for areas such as biological products and traditional Chinese medicine |
Key requirements
- Operate a compliant pharmaceutical quality system
- Apply the relevant product appendix (e.g. sterile)
- Maintain validation and data integrity
Implementation tips
- Engage in-country regulatory expertise for NMPA inspection and dossier-language requirements
Revision notes
The 2010 Revision (effective 2011) substantially upgraded China GMP; the 2019 Drug Administration Law introduced the MAH system.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The NMPA became a member of the International Council for Harmonisation (ICH) in 2017, and the 2010 GMP Revision was drafted to move Chinese GMP toward international expectations, adopting a structure close to EU GMP with a main text plus appendices. ICH membership commits China to progressively implementing ICH guidelines, which drives convergence — while the binding requirement for a Chinese site remains the national GMP under the Drug Administration Law.
China GMP (2010 Revision): frequently asked questions
Quick answers to common questions about China GMP (2010 Revision).
What law underpins China’s GMP?
China’s GMP for drugs (2010 Revision) is administered under the Drug Administration Law and its implementing regulations, and is enforced by the NMPA and its provincial counterparts as a condition of the drug-manufacturing licence.
Is China an ICH member?
Yes. The NMPA joined the International Council for Harmonisation (ICH) in 2017, committing China to progressively implementing ICH guidelines and driving convergence with international norms.
How is China’s GMP structured?
Like EU GMP: a main text of general requirements plus a series of appendices covering specific areas such as sterile products, biological products and traditional Chinese medicine.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.